Patients with aHCC in the sorafenib (n = 48) and B-HAIC (n = 48) groups were comparable in terms of age, sex, preceding treatment ratio, tumor markers such as alpha fetoprotein (AFP) and DCP, and number of intrahepatic HCCs (Table S1). The gene discussed is AFP; the disease is neoplasm.